Skip to main content
Tech.euFundingExplorerBeta

GenSight Biologics

Develops innovative therapies for mitochondrial and neurodegenerative diseases

GenSight Biologics has raised €87M across 4 funding rounds from 6 investors, most recently a round in Jul 2025. Based in Paris, France; founded 2011; active in Healthtech. Data as of 28 Oct 2026.

Total raised
€87M
€87,174,457
Funding rounds
4
Investors
6
distinct backers
Active since
2013-04
latest 2025-07

Funding by year

EUR raised per year
GenSight Biologics — funding by year — interactive chart.
Data table
GenSight Biologics — funding by year
2013€32M
2015€32M
2017€23M
2025€500k

Signals

Medium confidence
Raise-next likelihood40
base rate 30% for Other
  • ▲ In typical raise window
  • ▼ Down/flat last round
Exit likelihood11
base rate 11% (2+ rounds)
  • ▲ €30M+ raised
  • ▲ 4 rounds raised
  • ▼ No recent equity round (debt-only or quiet)

Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

4 rounds
DateStageAmountInvestors
2025-07-18Other€500kundisclosed investorsView deal →
2017-09-14Other€23M—View deal →
2015-07-01Series B€32MAbingworth LLP,Fidelity,HealthCap,Index Ventures,Novartis Venture FundView deal →
2013-04-01Series A€32MAbingworth LLP,Index Ventures,Novartis Venture FundView deal →

Similar companies

same sector or country

Global coverage: FundingData